DMOG

製品コード:S7483 別名:Dimethyloxalylglycine

For research use only.

DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.

DMOG化学構造

CAS No. 89464-63-1

サイズ 価格(税別)
10mM (1mL in DMSO) JPY 21900
JPY 18100
JPY 34200
JPY 56200

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(28)

製品安全説明書

Hydroxylase阻害剤の選択性比較

相関Hydroxylase製品

生物活性

製品説明 DMOG (Dimethyloxalylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolylhydroxylase, leading to stabilisation and accumulation of HIF-1α protein in the nucleus. DMOG enhances autophagy.
ターゲット
HIF prolyl hydroxylase [1]
体外試験

DMOG shows only weakly active in the microsomal system, but efficiently suppresses hydroxyproline synthesis in intact cells. [1] DMOG reduces FGF-2-induced proliferation and cyclin A expression by inhibiting prolyl hydroxylase activity in HPASMC. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human SR cell M4OxXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\GXmlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW3PVQ3KM7:TR?= Mn;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human LB996-RCC cell MoniS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXXOOlBiUW6qaXLpeIlwdiCxZjDoeY1idiCOQkm5Ok1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[4O|ch|ryP MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human LOUCY cell M4Tifmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NULCbY94UW6qaXLpeIlwdiCxZjDoeY1idiCOT2XDXUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjN2OUOg{txO M{i2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human KS-1 cell MoDKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEH0V|NKdmirYnn0bY9vKG:oIHj1cYFvKEuVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4zPTV5IN88US=> NE[5WFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human U-698-M cell MnLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV\G[INTUW6qaXLpeIlwdiCxZjDoeY1idiCXLU[5PE1OKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTNwM{OwOkDPxE1? NYK4RZhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human A3-KAW cell NILW[mpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PjfmlvcGmkaYTpc44hd2ZiaIXtZY4hSTNvS1HXJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvQDF5NDFOwG0> NXi2bIlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human BL-70 cell NEG2XWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzUTY5pcWKrdHnvckBw\iCqdX3hckBDVC15MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlk1OjNizszN Mmi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human DMS-273 cell MoiyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU46PjVizszN MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human CAL-39 cell MnvJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlMzPzdizszN M1;z[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human KYSE-410 cell NHfW[IRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlAvQDF7NzFOwG0> NWLPS4hxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human YT cell M3L5[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PCN2lvcGmkaYTpc44hd2ZiaIXtZY4hYVRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Mz6zPVg1KM7:TR?= NVPycoxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human LC-2-ad cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXRVXczUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2yMYFlKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjRwNUW3N{DPxE1? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human COR-L105 cell NELBOnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlYvPDR|NjFOwG0> MnrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human CAL-12T cell NGfU[IhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOk42PTB{IN88US=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human KU812 cell MnHwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkiuOFU4QSEQvF2= NXTDVlZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human OPM-2 cell NXPpNmdXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIi2VnRKdmirYnn0bY9vKG:oIHj1cYFvKE:STT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvQDJ{NzFOwG0> M3;hRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human SW982 cell MlfaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4\RcmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{44ODB5IN88US=> NYDKN3JNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human HH cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{TGUGlvcGmkaYTpc44hd2ZiaIXtZY4hUEhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|ND6wNlM2KM7:TR?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human RS4-11 cell NGHl[5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;ZblFXUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC5zOEC2JO69VQ>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human BEN cell M2m4Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NInmWI5KdmirYnn0bY9vKG:oIHj1cYFvKEKHTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO2MlgyQDdizszN M4r6NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human CCRF-CEM cell NYLzW|B4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXzJcohq[mm2aX;uJI9nKGi3bXHuJGNEWkZvQ1XNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|cvPzd{OTFOwG0> M4XudFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human EW-13 cell NYPTWIkxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1G2N2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU4xPDhzIN88US=> M3TOdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human NCI-H2228 cell M2fHNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3LJbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDJwOEG4JO69VQ>? MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human KE-37 cell NHrRTHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3rhOGlvcGmkaYTpc44hd2ZiaIXtZY4hU0VvM{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20N{4zQTF3IN88US=> M3LqVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human A4-Fuk cell MkTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{HuOWlvcGmkaYTpc44hd2ZiaIXtZY4hSTRvRoXrJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvODN4NDFOwG0> NIrKUHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human MZ1-PC cell NWHyb4hqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJG1bOS2SQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1Mlk5QDhizszN NH\SfI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human MLMA cell M3e0d2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEDr[JNKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Ok4{Ojl{IN88US=> NIjuUYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human EB-3 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlK2TY5pcWKrdHnvckBw\iCqdX3hckBGSi1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NEmuOVc6OiEQvF2= MlL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human 293T cells  NVXUcW1VTnWwY4Tpc44h[XO|YYm= NE[2S2ozNjVibV2= MUnJcohq[mm2aX;uJI9nKEqPSlSyMY1m\GmjdHXkJGg{UzN4IHTlcYV1cHmuYYTpc44hcW5iaIXtZY4hOjl|VDDj[YxteyCjdDCyMlUhdU1? NX\FSXhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOVkyPjdpPkG5N|U6OTZ5PD;hQi=>
アッセイ
Methods Test Index PMID
Western blot HIF-1α ; p-CHK1 / CHK1 / p-p53 / p53 / p-CHK2 / CHK2 / p-ATM / ATM ; WNT11 / HIF-2α 29555474 22797300 26861754
Immunofluorescence HIF1α 28955984
体内試験

DMOG inhibits endogenous HIF inactivation, and induces angiogenesis in ischaemic skeletal muscles of mice. [2] Up-regulation of hypoxia-inducible factor-1α by DMOG enhances the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[3]

  • 細胞株:VSMC cells
  • 濃度: ~100 μM
  • 反応時間:72-96 hours
  • 実験の流れ:

    To analyze DNA synthesis as an index of cellular proliferation, VSMC are plated in 48-well plates (5,000 per square centimeter) in growth medium, incubated overnight, and serum-deprived (1% FCS) for 24 h. Replicate wells are then stored at −70°C for baseline (day 0) cell counts, and fresh medium with or without growth factors is added to the remaining wells, which are incubated 72-96 h in 20 or 5% O2. Days 0 and 3 or 4 cell counts are determined by lysing cells in a buffer containing a fluorescent dye, which has minimal fluorescence by itself but fluoresces when bound to DNA or RNA. Absolute cell numbers are calculated by comparing the fluorescence of specimens with that of a standard curve similarly prepared using a known number of cells.

動物試験:

[2]

  • 動物モデル:Mice (C57Bl6)
  • 投薬量:8 mg in 0.5 ml saline
  • 投与方法:i.p.

溶解度 (25°C)

体外

化学情報

分子量 175.14
化学式

C6H9NO5

密度 1.246 g/mL
CAS No. 89464-63-1
Storage 3年 -20°C
2年 -80°C in solvent
Smiles COC(=O)CNC(=O)C(=O)OC

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: DMOGを買う | DMOG ic50 | DMOG供給者 | DMOGを購入する | DMOG費用 | DMOG生産者 | オーダーDMOG | DMOG化学構造 | DMOG分子量 | DMOG代理店